Table 2 Efficacy results in patients without prior antimicrobial failure in the mCRE-MITT population [17]

From: Clinical Outcomes of Patient Subgroups in the TANGO II Study

Efficacy endpoints (mCRE-MITT) Meropenem–vaborbactam (n = 23) Best available therapy (n = 15) Absolute difference (95% CI)
Clinical cure at TOC 16 (69.6) 4 (26.7)  + 42.9 (+ 13.7 to + 72.1)
Clinical cure at EOT 19 (82.6) 5 (33.3)  + 49.3 (+ 20.8 to + 77.7)
Microbiologic curea at EOT 19 (82.6) 6 (40.0)  + 42.6 (+ 13.4 to + 71.8)
Microbiologic curea at TOC 16 (69.6) 5 (33.3)  + 36.2 (+ 5.9 to + 66.6)
Day-28 mortality 1 (4.3) 5 (33.3)  − 29.0 (− 54.3 to − 3.7)
  1. Reused with permission under Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) from Bassetti et al. [17]. https://doi.org/10.1007/s12325-019-00981-y
  2. CI confidence intervals, EOT end of therapy, mCRE-MITT microbiologic carbapenem-resistant Enterobacteriaceae modified intent-to-treat, TOC test of cure
  3. aMicrobiologic cure was defined as microbial eradication or presumed eradication